Pharmacy, Health Sciences & Exercise Science
Event Title
An Evaluation of Fidaxomicin Use in a Community Health System
Document Type
Oral Presentation
Location
Indianapolis, IN
Subject Area
Pharmacy, Health Sciences & Exercise Science
Start Date
11-4-2014 8:30 AM
End Date
11-4-2014 10:00 AM
Sponsor
Jarrett Amsden (Butler University)
Description
Background: Fidaxomicin is a narrow spectrum, non-absorbed antibiotic that is indicated for the treatment of Clostridium difficile infection (CDI). Unfortunately the acquisition cost of fidaxomicin limits its routine use in the inpatient setting, therefore hospitals have had to implement cost containment strategies for it use. The purpose of this study is to evaluate the use of fidaxomicin in a community health system. This study is also part of a larger national study evaluating the use of fidaxomicin in the United States.
Study objectives: To characterize the use of fidaxomicin in theCommunity Health Network. The secondary objective is to evaluate the recurrence and re-hospitalization rates of patients treated with fidaxomicin.
Methods: This study is a retrospective case series evaluating all patients treated with fidaxomicin between June 1, 2011 and May 31, 2013 in the Community Health Network, Indianapolis, IN. Applicable patient and clinical data will be collected during the initial inpatient treatment course. Additionally, all patients will be evaluated for 90 days following their initial hospital discharge to assess for recurrent CDI. Patients will be included if they have at least one documented CDI and were treated with fidaxomicin. Patients will be excluded if they are less than 18 or older than 89 years of age, pregnant or prisoners. Patients will also be excluded if the CDI episode, CDI severity, or recurrence cannot be determined. All data will be collected on a uniform data collection sheet and analyzed using descriptive statistics.
Significance: The results of this study will help Community Health Network practitioners determine how fidaxomicin is being utilized, as well as determining patient outcomes.
Disclosure: Primary investigators of this study have nothing to disclose. Optimer Pharmaceuticals, Inc is funding the national research and analysis, conducted by the University of Houston.
An Evaluation of Fidaxomicin Use in a Community Health System
Indianapolis, IN
Background: Fidaxomicin is a narrow spectrum, non-absorbed antibiotic that is indicated for the treatment of Clostridium difficile infection (CDI). Unfortunately the acquisition cost of fidaxomicin limits its routine use in the inpatient setting, therefore hospitals have had to implement cost containment strategies for it use. The purpose of this study is to evaluate the use of fidaxomicin in a community health system. This study is also part of a larger national study evaluating the use of fidaxomicin in the United States.
Study objectives: To characterize the use of fidaxomicin in theCommunity Health Network. The secondary objective is to evaluate the recurrence and re-hospitalization rates of patients treated with fidaxomicin.
Methods: This study is a retrospective case series evaluating all patients treated with fidaxomicin between June 1, 2011 and May 31, 2013 in the Community Health Network, Indianapolis, IN. Applicable patient and clinical data will be collected during the initial inpatient treatment course. Additionally, all patients will be evaluated for 90 days following their initial hospital discharge to assess for recurrent CDI. Patients will be included if they have at least one documented CDI and were treated with fidaxomicin. Patients will be excluded if they are less than 18 or older than 89 years of age, pregnant or prisoners. Patients will also be excluded if the CDI episode, CDI severity, or recurrence cannot be determined. All data will be collected on a uniform data collection sheet and analyzed using descriptive statistics.
Significance: The results of this study will help Community Health Network practitioners determine how fidaxomicin is being utilized, as well as determining patient outcomes.
Disclosure: Primary investigators of this study have nothing to disclose. Optimer Pharmaceuticals, Inc is funding the national research and analysis, conducted by the University of Houston.